Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

REFERENCES

• Miller K, NeiIan B, Sze DM. Development of Taxol and other endophyte produced anti-cancer agents. Recent Pat Anticancer Drug Discov 2008; 3 (1): 14–19.
   PubMed Web of Science ®Google Scholar
• Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993; 15: 141–147.
   PubMedGoogle Scholar
• Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82 (15): 1247–1259.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Von Minckwitz G. Molecular basis for the development for novel taxanes in the treatment of metastatic breast cancer. Eur J Cancer 2008; 6 (10): 3–11.
   Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, GraIla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990; 8 (7): 1263–1268.
   PubMed Web of Science ®Google Scholar
• Singla AK, Gary A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235 (1-2): 179–192.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37 (13): 1590–1598.
   PubMed Web of Science ®Google Scholar
• Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of pre-medication regimens. Br J Cancer 2004; 90 (2): 304–305.
   PubMed Web of Science ®Google Scholar
• Mass B, Huber C, Kramer I. Plasticizer extraction of Taxol infusion solution from various infusion devices. Pharm World Sci 1996; 18 (2): 78–82.
   PubMedGoogle Scholar
• Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59 (7): 1454–1457.
   PubMed Web of Science ®Google Scholar
• Piccart M. Nab-paclitaxel : a targeted chemotherapy to improve outcomes in metastatic breast cancer. Asia-Pacific J Oncol Hematol 2009; 1 (1): 5–12.
   Google Scholar
• van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81 (2): 330–335.
   PubMed Web of Science ®Google Scholar
• Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42 (7): 665–685.
   PubMed Web of Science ®Google Scholar
• Winer EP, Berry DA, Woolf S, Duggan D, Komblith A, Harris LN, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22 (11): 2061–2068.
   PubMed Web of Science ®Google Scholar
• Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007; 13: 345–357.
   PubMedGoogle Scholar
• Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007; 2 (4): 415–423.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12 (4): 1317–1324.
   PubMed Web of Science ®Google Scholar
• Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000; 1478 (1): 61–68.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60 (8): 876–885.
   PubMed Web of Science ®Google Scholar
• Paal K, Muller J, Hegeas L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001; 268 (7): 2187–2191.
   PubMedGoogle Scholar
• Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2 (2): 59–64.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8 (5): 1038–1044.
   PubMed Web of Science ®Google Scholar
• Agence Française de Sécurité Sanitaire et des Produits de Santé, Avail-able from URL: http://afssaps-prd.afssaps.fr/php/ecodex/frames.php? specid= 61347058&typedoc=R&ref=R0089587.htm [Accessed 2010 Jul 10].
   Google Scholar
• Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formu-lated in Cremophor (Taxol). Clin Cancer Res 2005; 11 (11): 4136–4143.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14 (13): 4200–4205.
   PubMed Web of Science ®Google Scholar
• Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister By, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7 (11): 850–856.
   PubMed Web of Science ®Google Scholar
• Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19 (22): 4216–4223.
   PubMed Web of Science ®Google Scholar
• Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16 (10): 3362–3368.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23 (25): 6019–6026.
   PubMed Web of Science ®Google Scholar
• TUbiarla-HUlin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 2005; 31 (4): S3–9.
   Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27 (22): 3611–3619.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23 (31): 7794–7803.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast can-cer. N Engl J Med 2007; 357: 2666–2676.
   PubMed Web of Science ®Google Scholar
• Conlin AK, Hudis CA, Bach A, et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with beva-cizumab as first-line therapy for HER2-negative metastatic breast cancer. Proc ASCO 2009: Abstract 1006.
   Google Scholar
• Link JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albu-min-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Can-cer 2007; 7 (10): 779–783.
   PubMed Web of Science ®Google Scholar
• Jones J, Takeda A, Tan SC, Cooper K, Loveman E, Clegg A. Gem-citabine for the treatment of metastatic breast cancer. Health Technol Assess 2009; 13 (2): 1–7.
   Google Scholar
• Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albu-min-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gem-citabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009; 20 (3): 449-53.
   Google Scholar
• Surveillance Epidemiology and End Results Available from URL : http://seer.cancer.gov/statistics/ [Accessed the 2010 Jul 10].
   Google Scholar
• Mayer EL, Burstein FIJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007; 21 (2): 257–72.
   PubMed Web of Science ®Google Scholar
• Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep 2007; 9 (1): 22–30.
   PubMedGoogle Scholar
• Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; 4: CD004421.
   PubMedGoogle Scholar
• Friedrich M, Diesing D, Villena-Heinsen C, Felberbaum R, Kolberg HC, Diedrich K. Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur J Gynaecol Oncol 2004; 25 (1): 66–70.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hor-tobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6 (2): 133–146.
   PubMed Web of Science ®Google Scholar
• Abraham J. Nab-paclitaxel as first line therapy for metatstatic breast cancer. Commun Oncol 2008; 5 (7): 1–7.
   Google Scholar
• Mitchell PL, Sasser R, Chipman M, Grigg A, Mansfield R, Cebon J, et al. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Ann Oncol 2004; 15 (4): 585–589.
   PubMed Web of Science ®Google Scholar
• Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robin-son BA, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24 (31): 4963–4970.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Available from URL: http://www.ema. europa.eu/humandocs/PDFs/EPAR/abraxane/H- 778-PI-en.pdf [Accessed 2010 Jun 16].
   Google Scholar
• Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999; 4 (5): 408–416.
   PubMedGoogle Scholar
• Fumoleau P. Efficacy and safety of docetaxel in clinical trials. Am J Health Syst Pharm 1997; 54 (24): S19–24.
   PubMedGoogle Scholar
• Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92 (13): 1074–1080.
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve pa-tients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27 (3): 145–157.
   PubMed Web of Science ®Google Scholar
• Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17 (8): 1263–1268.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26 (4): 639–643.
   PubMed Web of Science ®Google Scholar
• Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21 (15): 2933–2939.
   PubMed Web of Science ®Google Scholar
• Allerton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24 ( 18S): 7127.
   Google Scholar
• Socinski MA, Bondarenko IN, Karaseva NA, Makhson A, I. Vynny-chenko I, I. Okamoto I, et al. Results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small-cell lung cancer. ASCO Annual 2010 : Abstract LBA7511.
   Google Scholar
• Reynolds C, Barrera D, Jotte R, Spira Al, Weissman C, Boehm KA, et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009; 4 (12): 1537–1543.
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. Cancer 2010; 116 (1): 155–163.
   PubMed Web of Science ®Google Scholar
• Gogas H, Bafaloukos D, Bedikian AY. The role of taxanes in the treat-ment of metastatic melanoma. Melanoma Res 2004; 14 (5): 415–420.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. Melanoma Study Group. Bc1-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24 (29): 4738-4745.
   Google Scholar
• Masellis AM, Sielaff TD, Bender GP. Successful treatment of metasta-tic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol 2009; 14 (5): 478–81.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-pa-clitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27 ( 15): Abstract 4525.
   Google Scholar
• Hosein PJ, Lopes GD Jr., Gomez CM, Pastorini VU, Macintyre J, Easey M, et al. A phase 11 trial of nab-paclitaxel (NP) in patients with ad-vanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. J Clin Oncol 2010; 28 ( 15): Abstract 4120.
   Google Scholar
• Boruta DM 2nd, Fowler WC Jr, Gehrig PA, Boggess JF, Walton LA, Van Le L. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest. 2003; 21 (5): 675–681.
   Google Scholar
• Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. Phase II evaluation of nanoparticle albumin-bound pacli-taxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fal-lopian tube cancer. J Clin Oncol 2009; 27 (9): 1426–1431.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady W, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nab-paclitaxel in the treatment of recur-rent or persistent platinum-resistant ovarian, fallopian tube, or primary peri-toneal cancer: A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2010; 28 ( 15): Abstract 5010.
   Google Scholar
• T. D. Tillmanns, M. P. Lowe, L. S. Schwartzberg, M. S. Walker, E. J. Stepanski. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peri-toneal carcinoma. J Clin Oncol 2010; 28: (15): Abstract 5009.
   Google Scholar